Daniel Spratt and Alicia Morgans discuss clinical outcomes of patients with Gleason score 9-10 prostate cancer after definitive treatment. Long-term Survival in Men with Gleason Score 9-10 Treated ...
(UroToday.com) The 2025 SUO annual meeting featured a urothelial carcinoma session and a presentation by Dr. Reuben Ben-David discussing preoperative ctDNA predicting upstaging and recurrence in ...
Prostate Recurrence Detection Using Imaging With PSMA PET/MRI Post-high Intensity Focused Ultrasound
Evidence of metastatic disease on PSMA PET/CT. Allergy to POSLUMA or gadolinium. Inability to tolerate MRI due to claustrophobia or posture/back-hip issues.
UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.
The transforming growth factor-beta (TGF-β) signaling pathway plays a critical role in tumor development and includes bone morphogenetic proteins (BMPs). Among them, BMP7 is essential for renal ...
ESMO 2024, Prostate Cancer, transdermal estradiol, LHRH agonists, Transdermal Estradiol Versus LHRH Agonists, Androgen Suppression in M0 Prostate Cancer, STAMPEDE trial.
(UroToday.com) The 2024 American Society of Clinical Oncology (ASCO) annual meeting featured a session on prostate cancer, and a presentation by Dr. Daniel Petrylak discussing initial results of a ...
EAU 2024 trial design of SunRISe-3, TAR-200 plus cetrelimab or TAR-200 versus intravesical BCG, BCG-naive high-risk non–muscle-invasive bladder cancer, transure ...
(UroToday.com) The 2022 GU ASCO Annual meeting included a prostate cancer session highlighting work from Dr. Zachery R. Reichert and colleagues presenting results of the TRAP trial, targeting ...
(UroToday.com) In this presentation, Dr. Fred Saad presented results of the PROpel study. PROpel is a randomized phase III trial of abiraterone plus olaparib versus abiraterone plus placebo as ...
(UroToday.com) Most patients newly diagnosed with bladder cancer have non-muscle invasive disease (NMIBC). For patients with intermediate or high-risk NMIBC and those with carcinoma in situ (CIS), ...
(UroToday.com) In this presentation, Dr. Michael Morris presented the results of the phase 3 VISION trial evaluating the radiopharmaceutical lutetium-PSMA (Lu-PSMA) in patients with metastatic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback